Cancer vaccine development has entered a new phase as researchers advance mRNA and peptide-based immunizations designed to train the immune system to target and destroy malignant cells. According to the National Cancer Institute, these investigational therapies work differently from traditional preventative shots by focusing on neoantigens unique to a patient’s specific tumor.
How Therapeutic Cancer Vaccines Work
Unlike preventative vaccines that stop infectious diseases before they start, therapeutic cancer vaccines treat existing tumors by stimulating a patient’s adaptive immune system. According to Nature Reviews Cancer, these treatments isolate mutated proteins found exclusively on cancer cells, prompting T-cells to track down and eliminate those specific cells while sparing healthy tissue.
Clinical Trials and Current Research
Clinical trials evaluating personalized mRNA cancer vaccines in combination with immunotherapy drugs like pembrolizumab show a reduction in recurrence rates for melanoma and non-small cell lung cancer, according to data published in the New England Journal of Medicine. Researchers continue to evaluate dosing schedules and adjuvant settings to determine how many booster doses are necessary to maintain long-term immune surveillance.
Frequently Asked Questions
What is the difference between a preventative and a therapeutic cancer vaccine?
Preventative vaccines, such as the HPV vaccine, stop infections that can lead to cancer. Therapeutic vaccines are administered after a diagnosis to train the immune system to attack an existing tumor.
Are cancer vaccines commercially available?
Most cancer vaccines remain in clinical trials or are approved only for specific indications, such as sipuleucel-T for advanced prostate cancer, according to the U.S. Food and Drug Administration.
Worth a look